Xeris Biopharma Holdings (XERS) Amortization - Intangibles (2021 - 2026)

Xeris Biopharma Holdings has reported Amortization - Intangibles for 6 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization - Intangibles changed 0.0% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (changed 0.01% YoY), and the FY2025 full-year result was $10.8 million, changed 0.0% from the prior year.
• Amortization - Intangibles for Q1 2026 stood at $2.7 million, roughly flat from $2.7 million in the prior quarter.
• The five-year high for Amortization - Intangibles was $2.7 million in Q1 2022, with the low at $2.7 million in Q2 2022.
• Historically, Amortization - Intangibles has averaged $2.7 million across 5 years, with a median of $2.7 million in 2022.
• Annual changes were most pronounced in 2022 — Amortization - Intangibles jumped 392.91% — and 2025, when it slipped 0.04%.
• Xeris Biopharma Holdings' Amortization - Intangibles stood at $2.7 million in 2022, then changed by 0.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then changed by 0.0% to $2.7 million in 2025, then decreased by 0.04% to $2.7 million in 2026.
• The last three Amortization - Intangibles figures came in at $2.7 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.